Literature DB >> 21324464

Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population.

Meixiang Xiang1, Jiusong Sun, Yan Lin, Jie Zhang, Han Chen, Dan Yang, Jianan Wang, Guo-Ping Shi.   

Abstract

Tryptase and chymase are unique mast cell proteases that are essential in atherogenesis. This study establishes a link between serum tryptase and chymase levels and human coronary heart diseases (CHD) in a cohort of 270 subjects. Serum tryptase levels were significantly higher in patients with substantial CHD than in those without substantial CHD (substantial CHD vs. unsubstantial CHD: 7.81 ± 0.52 ng/mL vs. 6.11 ± 0.51 ng/mL, P=0.002). After subgrouping the substantial CHD patients into those with acute myocardial infarction (AMI) and those with unstable or stable angina pectoris (UAP or SAP), we demonstrated that serum tryptase levels were nearly doubled in AMI patients as compared with unsubstantial CHD patients (11.13 ± 1.55 ng/mL vs. 6.11 ± 0.51 ng/mL, P<0.01), and significantly higher than in UAP patients (7.19 ± 0.62 ng/mL, P<0.05) or SAP patients (6.80 ± 0.94 ng/mL, P<0.05). Although Spearman's correlation test showed that serum tryptase correlated significantly with age (P=0.014) and weakly with fasting glucose (P=0.084), total cholesterol (P=0.071), low-density lipoprotein (P=0.063), and triglyceride (P=0.058), serum tryptase levels remained significantly higher in substantial CHD patients than in unsubstantial CHD patients in a multiple linear regression test after adjusting for all these confounders (P=0.008). Serum chymase levels were also higher in AMI patients (27.64 ± 7.57 ng/mL) or UAP patients (24.62 ± 8.06 ng/mL) than in SAP patients (15.20 ± 0.81 ng/mL) or unsubstantial CHD patients (16.84 ± 0.56 ng/mL), although such differences were not statistically significant. Spearman's correlation test revealed that serum chymase levels correlated significantly only with fasting glucose levels (P=0.019), and CHD status did not affect chymase levels before and after adjusting for all confounders. Our observations suggest that serum tryptase is an independent biomarker for coronary plaque stability in this Chinese population.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21324464      PMCID: PMC3070056          DOI: 10.1016/j.atherosclerosis.2011.01.006

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  40 in total

Review 1.  Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions.

Authors:  K Oörni; M O Pentikäinen; M Ala-Korpela; P T Kovanen
Journal:  J Lipid Res       Date:  2000-11       Impact factor: 5.922

2.  Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta.

Authors:  Yoshinari Uehara; Hidenori Urata; Munehito Ideishi; Kikuo Arakawa; Keijiro Saku
Journal:  Cardiovasc Res       Date:  2002-09       Impact factor: 10.787

3.  Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol.

Authors:  Miriam Lee; Christian P Sommerhoff; Arnold von Eckardstein; Frank Zettl; Hans Fritz; Petri T Kovanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

4.  Role of resident mast cells and macrophages in the neutrophil migration induced by LTB4, fMLP and C5a des arg.

Authors:  R A Ribeiro; M V Souza-Filho; M H Souza; S H Oliveira; C H Costa; F Q Cunha; H S Ferreira
Journal:  Int Arch Allergy Immunol       Date:  1997-01       Impact factor: 2.749

5.  Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model.

Authors:  M Muramatsu; J Katada; I Hayashi; M Majima
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

6.  Angiotensin-converting enzyme-independent angiotensin formation in a human model of myocardial ischemia: modulation of norepinephrine release by angiotensin type 1 and angiotensin type 2 receptors.

Authors:  R Maruyama; E Hatta; K Yasuda; N C Smith; R Levi
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

7.  No long-lasting or intermittent mast cell activation in acute coronary syndromes.

Authors:  P L van Haelst; J R Timmer; H J Crijns; H F Kauffman; R O Gans; J J van Doormaal
Journal:  Int J Cardiol       Date:  2001-03       Impact factor: 4.164

8.  Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase.

Authors:  K A Lindstedt; Y Wang; N Shiota; J Saarinen; M Hyytiäinen; J O Kokkonen; J Keski-Oja; P T Kovanen
Journal:  FASEB J       Date:  2001-06       Impact factor: 5.191

9.  Mast cell heterogeneity in the human uvea.

Authors:  C A May
Journal:  Histochem Cell Biol       Date:  1999-11       Impact factor: 4.304

10.  Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in Apolipoprotein E knockout mice.

Authors:  Man Huang; Xinzhu Pang; Richard Letourneau; William Boucher; Theoharis C Theoharides
Journal:  Cardiovasc Res       Date:  2002-07       Impact factor: 10.787

View more
  17 in total

Review 1.  Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases.

Authors:  Jia-Ming Xu; Guo-Ping Shi
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

2.  Mast cell derived carboxypeptidase A3 is decreased among patients with advanced coronary artery disease.

Authors:  Łukasz Lewicki; Janusz Siebert; Tomasz Koliński; Karolina Piekarska; Magdalena Reiwer-Gostomska; Radosław Targoński; Piotr Trzonkowski; Natalia Marek-Trzonkowska
Journal:  Cardiol J       Date:  2018-03-07       Impact factor: 2.737

Review 3.  Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.

Authors:  Yanwen Qin; Guo-Ping Shi
Journal:  Pharmacol Ther       Date:  2011-05-12       Impact factor: 12.310

4.  Association between SNP rs1800875, serum chymase and immunoglobulin E levels in patients with coronary heart disease.

Authors:  Chun-Na Jin; Hong Ma; Yan Lin; Jian-An Wang; Mei-Xiang Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2011-08       Impact factor: 3.066

Review 5.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

6.  Successful treatment of prolonged cardiopulmonary arrest of Kounis syndrome during coronary angioplasty.

Authors:  Tomomi Akita; Masahito Kawata; Ayu Sakaguchi; Yukinori Kato; Hideya Suehiro; Hiroki Takada; Takeshi Matsuura; Kohei Kamemura; Yasutaka Hirayama; Kazumasa Adachi; Akira Matsuura; Susumu Sakamoto
Journal:  J Cardiol Cases       Date:  2015-12-08

7.  Increased level of soluble syndecan-1 in serum correlates with myocardial expression in a rat model of myocardial infarction.

Authors:  Juan Lei; Sheng Neng Xue; Wei Wu; Shu Xian Zhou; Yu Ling Zhang; Gui Yi Yuan; Jing Feng Wang
Journal:  Mol Cell Biochem       Date:  2011-08-14       Impact factor: 3.396

Review 8.  Mast cells as effectors in atherosclerosis.

Authors:  Ilze Bot; Guo-Ping Shi; Petri T Kovanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-07       Impact factor: 8.311

9.  [Screening and verification of plasma biomarkers for stable angina pectoris: a differential proteomic analysis].

Authors:  An-Na Shen; Shui-Wang Hu; Jing Huang; De-Zhong Zheng; Zhao-Ting Hu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

10.  Immunoglobulin E and mast cell proteases are potential risk factors of impaired fasting glucose and impaired glucose tolerance in humans.

Authors:  Zhen Wang; Hong Zhang; Xu-Hui Shen; Kui-Li Jin; Guo-Fen Ye; Wei Qiu; Li Qian; Bo Li; Yong-Hong Zhang; Guo-Ping Shi
Journal:  Ann Med       Date:  2012-10-30       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.